RT Journal Article
T1 PROPHETIC EU: Prospective Identification of Pneumonia in Hospitalized Patients in the Intensive Care Unit in European and United States Cohorts.
A1 Bergin, Stephen P
A1 Calvert, Sara B
A1 Farley, John
A1 Sun, Jie-Lena
A1 Chiswell, Karen
A1 Dieperink, Willem
A1 Kluytmans, Jan
A1 Lopez-Delgado, Juan Carlos
A1 Leon-Lopez, Rafael
A1 Zervos, Marcus J
A1 Kollef, Marin H
A1 Sims, Matthew
A1 Kabchi, Badih A
A1 Rubin, Daniel
A1 Santiago, Jonas
A1 Natarajan, Mukil
A1 Tenaerts, Pamela
A1 Fowler, Vance G
A1 Holland, Thomas L
A1 Bonten, Marc J
A1 Hullegie, Sebastiaan J
K1 antibacterial agent
K1 bacterial pneumonia
K1 health care–associated pneumonia
K1 intensive care unit
K1 mechanical ventilator
AB The prospective identification of patients at high risk for hospital-acquired/ventilator-associated bacterial pneumonia may improve clinical trial feasibility and foster antibacterial development. In a prior study conducted in the United States, clinical criteria were used to prospectively identify these patients; however, these criteria have not been applied in a European population. Adults considered high risk for pneumonia (treatment with ventilation or high levels of supplemental oxygen) in the intensive care units of 7 European hospitals were prospectively enrolled from June 12 to December 27, 2017. We estimated the proportion of high-risk patients developing pneumonia according to US Food and Drug Administration guidance and a subset potentially eligible for antibacterial trial enrollment. We compared patient characteristics, treatment exposures, and pneumonia incidence in a European cohort and a previously described US cohort. Of 888 high-risk patients, 211/888 (24%) were treated for possible pneumonia, and 150/888 (17%) met the Food and Drug Administration definition for hospital-acquired/ventilator-associated bacterial pneumonia. A higher proportion of European patients treated for possible pneumonia met the pneumonia definition (150/211 [71%] vs 537/1464 [37%]; P  Clinical criteria prospectively identified high-risk patients with high rates of pneumonia in the European cohort. Despite higher rates of established risk factors and incident pneumonia, European patients were significantly less likely to receive antibiotics for possible pneumonia than US patients. Different treatment practices may contribute to lower rates of antibacterial trial enrollment in the United States.
SN 2328-8957
YR 2022
FD 2022-05-09
LK http://hdl.handle.net/10668/19824
UL http://hdl.handle.net/10668/19824
LA en
DS RISalud
RD Aug 29, 2025